WO2001017480A3 - Methods and compositions for preventing and treating urinary tract disorders - Google Patents

Methods and compositions for preventing and treating urinary tract disorders Download PDF

Info

Publication number
WO2001017480A3
WO2001017480A3 PCT/US2000/024685 US0024685W WO0117480A3 WO 2001017480 A3 WO2001017480 A3 WO 2001017480A3 US 0024685 W US0024685 W US 0024685W WO 0117480 A3 WO0117480 A3 WO 0117480A3
Authority
WO
WIPO (PCT)
Prior art keywords
urinary tract
urinary
methods
compositions
preventing
Prior art date
Application number
PCT/US2000/024685
Other languages
French (fr)
Other versions
WO2001017480A2 (en
Inventor
Gary W Neal
Original Assignee
Androsolutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Androsolutions Inc filed Critical Androsolutions Inc
Priority to AU73607/00A priority Critical patent/AU7360700A/en
Priority to EP00961687A priority patent/EP1214039A2/en
Publication of WO2001017480A2 publication Critical patent/WO2001017480A2/en
Publication of WO2001017480A3 publication Critical patent/WO2001017480A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/08—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to methods, compositions, devices and kits for the prevention and treatment of urinary tract disorders in mammals, including, but not limited to, urinary incontinence of any etiology, urinary hesitancy, fibrosis of the urinary tract, urinary dribbling, cystitis of any etiology, urinary frequency, and bladder cancer. The present invention provides methods for preventing and treating urinary tract disorders in mammals by administration of a therapeutic compound to mucosal membranes in the lower urinary tract of the mammal. The present invention also provides devices for administering a therapeutic compound to mucosal membranes in the lower urinary tract of the mammal.
PCT/US2000/024685 1999-09-09 2000-09-08 Methods and compositions for preventing and treating urinary tract disorders WO2001017480A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU73607/00A AU7360700A (en) 1999-09-09 2000-09-08 Methods and compositions for preventing and treating urinary tract disorders
EP00961687A EP1214039A2 (en) 1999-09-09 2000-09-08 Methods and compositions for preventing and treating urinary tract disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15290299P 1999-09-09 1999-09-09
US60/152,902 1999-09-09

Publications (2)

Publication Number Publication Date
WO2001017480A2 WO2001017480A2 (en) 2001-03-15
WO2001017480A3 true WO2001017480A3 (en) 2001-11-01

Family

ID=22544943

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/024676 WO2001017479A2 (en) 1999-09-09 2000-09-08 Methods and compositions for preventing and treating prostate disorders
PCT/US2000/024685 WO2001017480A2 (en) 1999-09-09 2000-09-08 Methods and compositions for preventing and treating urinary tract disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024676 WO2001017479A2 (en) 1999-09-09 2000-09-08 Methods and compositions for preventing and treating prostate disorders

Country Status (3)

Country Link
EP (2) EP1214039A2 (en)
AU (2) AU7360000A (en)
WO (2) WO2001017479A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
DE10103262A1 (en) * 2001-01-25 2002-08-01 Axel Schmidt-Dossi Suppository containing oxybutynin, useful for treatment of incontinence, avoids side effects and allows an increase in dose
TWI301164B (en) * 2001-10-12 2008-09-21 Phild Co Ltd
FR2850864B1 (en) * 2003-02-12 2007-04-13 Oreal USE OF A 15-HYDROXY PROSTAGLANDIN DEHYDROGENASE INHIBITOR TO PROMOTE PIGMENTATION OF SKIN OR PHANES
JP4584908B2 (en) * 2003-02-12 2010-11-24 ロレアル Use of inhibitors of 15-hydroxyprostaglandin dehydrogenase for stimulating pigmentation of skin or skin appendages
DE602004020337D1 (en) * 2004-08-11 2009-05-14 Boehringer Ingelheim Pharma Anticholinergic drugs for the treatment of urinary tract disorders
SG166106A1 (en) * 2005-09-29 2010-11-29 Bayer Schering Pharma Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
US7902260B2 (en) * 2007-02-28 2011-03-08 Kemphys Ltd. Medicament for preventive and/or therapeutic treatment of lower urinary tract symptom
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
CA2856673C (en) 2012-01-04 2018-08-21 Wellesley Pharmaceuticals, Llc Use of acetaminophen for reducing the frequency of urination
RU2019101864A (en) * 2012-07-27 2019-03-11 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи PHARMACEUTICAL COMPOSITION FOR TREATMENT OF URINE INCONTINENCE AND METHOD OF ITS USE
CA2979203A1 (en) 2015-03-08 2016-09-15 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating fibrosis
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
EP4125998A1 (en) 2020-03-30 2023-02-08 Trizell Ltd. Compositions and methods for treating cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1045701A (en) * 1989-11-17 1990-10-03 沈阳铁路局中心医院 The preparation method of medicine applied on urethra
US5085650A (en) * 1989-10-20 1992-02-04 Giglio Frank A Gynecological urethral suppository
GB2260902A (en) * 1991-09-12 1993-05-05 Eurocetus Bv Interleukin-2 and tumour necrosis factor for treating bladder cancer
US5598549A (en) * 1993-06-11 1997-01-28 At&T Global Information Solutions Company Array storage system for returning an I/O complete signal to a virtual I/O daemon that is separated from software array driver and physical device driver
WO1997005876A1 (en) * 1995-08-08 1997-02-20 Kummer Horst Dieter Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
WO1999002147A1 (en) * 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
WO1999009970A1 (en) * 1997-08-28 1999-03-04 Afferon Corporation Urinary incontinence therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037943B1 (en) * 1980-03-31 1985-08-14 Teijin Limited Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
SU1130345A1 (en) * 1981-12-10 1984-12-23 Киевский Научно-Исследовательский Институт Заболеваний Почек И Мочевыводящих Путей /Урологии/ Method of treatment of chronic urethroprostatitis
DE3408260A1 (en) * 1984-03-07 1985-09-26 Roshdy Dipl.-Chem. Dr. 5000 Köln Ismail Suppositories containing vitamin E
RU2024253C1 (en) * 1991-03-27 1994-12-15 Валентина Васильевна Малиновская Rectal suppositories and device for introduction thereof
US5480640A (en) * 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
AU7130696A (en) * 1995-09-19 1997-04-09 Schering Aktiengesellschaft Combination of beta-interferon for the treatment of prostate cancer
DE19540642A1 (en) * 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Use of phosphodiesterase I, IV and V inhibitors
US5877215A (en) * 1996-03-20 1999-03-02 Medical University Of South Carolina Method of treating neoplastic cells with prostaglandin and radiation treatment or prostaglandin and platinum-based anti-tumor agents
US6350467B1 (en) * 1996-12-31 2002-02-26 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
DE19739693A1 (en) * 1997-09-04 1999-03-11 Schering Ag Synergistic treatment of multiple sclerosis and other neurodegenerative disorders
PL207462B1 (en) * 1998-05-07 2010-12-31 Univ Tennessee Res Corp A method for chemoprevention of prostate cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5085650A (en) * 1989-10-20 1992-02-04 Giglio Frank A Gynecological urethral suppository
CN1045701A (en) * 1989-11-17 1990-10-03 沈阳铁路局中心医院 The preparation method of medicine applied on urethra
GB2260902A (en) * 1991-09-12 1993-05-05 Eurocetus Bv Interleukin-2 and tumour necrosis factor for treating bladder cancer
US5598549A (en) * 1993-06-11 1997-01-28 At&T Global Information Solutions Company Array storage system for returning an I/O complete signal to a virtual I/O daemon that is separated from software array driver and physical device driver
WO1997005876A1 (en) * 1995-08-08 1997-02-20 Kummer Horst Dieter Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
WO1999002147A1 (en) * 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
WO1999009970A1 (en) * 1997-08-28 1999-03-04 Afferon Corporation Urinary incontinence therapy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BARTOLETTI R ET AL: "INTERFERON ALPHA 2A IN SUPERFICIAL BLADDER CANCER PROPHYLAXIS TOLERATION AND LONG-TERM FOLLOW-UP. A PHASE I-II STUDY", ANTICANCER RESEARCH, vol. 11, no. 6, 1991, pages 2167 - 2170, XP000944007, ISSN: 0250-7005 *
DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; ZHONGZHONG LI ET AL: "PREPARATION OF MEDICINE APPLIED ON URETHRA", XP002154307 *
EROZENCI AHMET: "Treatment of superficial bladder tumours.", CERRAHPASA TIP DERGISI, vol. 27, no. 2, 1996, pages 104 - 110, XP002154306, ISSN: 1300-5227 *
KRANC DAVID M ET AL: "Prophylactic and therapeutic carboprost tromethamine bladder irrigation in rats with cyclophosphamide-induced hemorrhagic cystitis.", JOURNAL OF UROLOGY, vol. 148, no. 4, October 1992 (1992-10-01), pages 1326 - 1330, XP000943982, ISSN: 0022-5347 *
NSEYO UNYIME O ET AL: "Immunotherapy of bladder cancer.", SEMINARS IN SURGICAL ONCOLOGY, vol. 13, no. 5, 1997, pages 342 - 349, XP000944003, ISSN: 8756-0437 *
ULMSTEN U: "PROSTAGLANDINS AND THE URINARY TRACT", ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA SUPPLEMENT, no. 113, 1983, pages 55 - 58, XP000944010, ISSN: 0300-8835 *
VAIDYANATHAN S ET AL: "INTRAVESICAL APPLICATION OF A 15(S) 15 METHYL PROSTAGLANDIN F2-ALPHA SUPPOSITORY IN FEMALES WITH CHRONIC URINARY RETENTION", IRCS MEDICAL SCIENCE, vol. 11, no. 10, 1983, pages 921 - 922, XP000943963 *
WEIMAR G W ET AL: "5 FLUORO URACIL URETHRAL SUPPOSITORIES FOR THE ERADICATION OF CONDYLOMA ACUMINATA", JOURNAL OF UROLOGY, vol. 120, no. 2, August 1978 (1978-08-01), pages 174 - 175, XP000943988, ISSN: 0022-5347 *
WILLCOX R R: "FURACIN URETHRAL SUPPOSITORIES IN THE TREATMENT OF NON-GONOCOCCAL URETHRITIS", ACTA DERM VENER, vol. 38, no. 1, 1958, pages 68 - 77, XP000944006 *

Also Published As

Publication number Publication date
AU7360000A (en) 2001-04-10
WO2001017479A3 (en) 2001-09-20
AU7360700A (en) 2001-04-10
WO2001017479A2 (en) 2001-03-15
EP1214039A2 (en) 2002-06-19
WO2001017480A2 (en) 2001-03-15
EP1214038A2 (en) 2002-06-19
WO2001017479B1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
WO2001017480A3 (en) Methods and compositions for preventing and treating urinary tract disorders
WO2002026262A3 (en) Compositions for reducing side effects in chemotherapeutic treatments
WO2002069963A3 (en) Compositions comprising ferulic acid, caffeic acid, tannic acid or ellagic acid and their use for the preparation of a medicament for the treatment of dermatological disorders
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
EP1933833B8 (en) Therapy for the treatment of overactive bladder
WO2005066337A3 (en) Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
WO2006020727A3 (en) Methods for treating cns disorders by administration of agents to the nasal cavity
WO1996027375A3 (en) Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence
WO1999015159A3 (en) Methods for increasing apoe levels for the treatment of neurodegenerative disease
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2004045523A3 (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2003072048A3 (en) Symptomatic relief of gastrointestinal disorders
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
WO2000037064A3 (en) Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
WO2003070175A3 (en) Use of opioid compound to treat a neurologic or neurogenic disorder
IL169362A0 (en) Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions
WO2007044682A3 (en) Method for treating chronic pain
PT1337246E (en) UTILIZATION OF 6-DIMETHYLAMINOMETHYL-1-PHENYLCYLOHEXANE COMPOUNDS FOR URINARY INCONTINENCE THERAPY
IL146962A0 (en) Aminotetralin derivatives for the therapy of cardiovascular diseases
WO2002049634A3 (en) Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000961687

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000961687

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000961687

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP